# Avacta Group London Science Day a great success

- Link: https://www.directorstalkinterviews.com/avacta-group-london-science-day-a-great-success/412772832
- Published: 2019-04-23T15:31:48+01:00
- Author: Giles Arbor

In a recent article over at genengnews.com Sue Pearson discusses ‘Antibody Mimetics–
More effective treatments for solid tumors?’ and the use of **[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
Affirmers.

>  **Alastair Smith, Chief Executive told DirectorsTalk:**
> “The recent Avacta London Science Day was a great success bringing together world-
> leaders in cancer immunotherapies with an audience made up of shareholders, analysts,
> fund managers and press. Genetic Engineering and Biotechnology News have provided
> a review of the day and highlighted the power of small, potent antibody mimetics.”

You can read the full article here ‘[Antibody Mimetics – More effective treatments for solid tumors?’](https://www.genengnews.com/insights/antibody-mimetics/)

Avacta’s principal focus is on its proprietary Affimer® technology which is a novel
engineered alternative to antibodies that has wide application in Life Sciences 
for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings.
Affimer® technology has been designed to address many of these negative performance
issues, principally; the time taken to generate new antibodies, the reliance on 
an animal’s immune response, poor specificity in many cases, and batch to batch 
variability. Affimer® technology is based on a small protein that can be quickly
generated to bind with high specificity and affinity to a wide range of protein 
targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on
immuno-oncology as well as partnered development programmes. Avacta is commercialising
non-therapeutic Affimer® reagents through licensing to developers of life sciences
research tools and diagnostics.

Share on:
